Atea Pharmaceuticals (AVIR) Cash from Operations (2019 - 2026)

Atea Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 46391000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 51.79% year-over-year to 46391000.0; the TTM figure through Mar 2026 stood at 147859000.0 (down 17.17% YoY), while the FY2025 annual figure was 132031000.0, up 2.56% from the prior year.
• Cash from Operations for Q1 2026 stood at 46391000.0, down from 28223000.0 in the prior quarter.
• The five-year high for Cash from Operations was 16120000.0 in Q2 2023, with the low at 59009000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 29850000.0 (2023), against an average of 30605764.71.
• Peak annual rise in Cash from Operations reached 71.43% in 2022, while the deepest fall reached 250.47% in 2022.
• Atea Pharmaceuticals' Cash from Operations stood at 21545000.0 in 2022, then declined by 1.34% to 21834000.0 in 2023, then sank by 39.22% to 30397000.0 in 2024, then gained by 7.15% to 28223000.0 in 2025, then slumped by 64.37% to 46391000.0 in 2026.
• Business Quant data shows AVIR's Cash from Operations at 46391000.0 in Q1 2026, 28223000.0 in Q4 2025, and 40375000.0 in Q3 2025.